Novel expandable infusion catheter for the treatment of acute pulmonary embolism
Ended Project Grant Awarded Last action
- Award ID
- R44HL151032
- Recipient
-
Thrombolex, Inc. UEI FLEJLJPRT5K5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,900,213
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Funding
-
- $5,914,658.00 Federal
- $985,555.00 Non-federal
- Place of performance
- Doylestown, PA 18901, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $978,998 | $0 | |
| Amendment | $978,998 | $0 | |
| Amendment | $985,555 | $0 | |
| Amendment | $985,555 | $0 | |
| Amendment | $985,555 | $985,555 | |
| Original award | $999,997 | $0 |
Quick answers
Who received award R44HL151032?
R44HL151032 was awarded to Thrombolex, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on April 5, 2020.
How much is award R44HL151032 worth?
$6,900,213 has been obligated on R44HL151032: $5,914,658 in federal funding and $985,555 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award